AC Immune SA ACIU
NASDAQ
| 06/30/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | -0.01% | -411.54% | -2.06% | -3.61% |
| Total Depreciation and Amortization | -- | 36.11% | 25.29% | 24.62% | 7.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 195.68% | 106.50% | -70.38% | 746.45% |
| Change in Net Operating Assets | -- | -118.67% | 81.99% | -96.83% | -112.33% |
| Cash from Operations | -- | -405.80% | -40.21% | -123.41% | -1,887.09% |
| Capital Expenditure | -- | -30.63% | 62.90% | -501.33% | -41.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 573.99% | 1,266.14% | 135.08% | 114.14% |
| Cash from Investing | -- | 559.78% | 1,168.70% | 134.53% | 112.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -52.05% | -50.00% | -47.40% | -51.50% |
| Issuance of Common Stock | -- | -- | -- | -97.78% | -- |
| Repurchase of Common Stock | -- | 96.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 120.83% | 99.04% |
| Cash from Financing | -- | -45.65% | -58.75% | -336.44% | 63.53% |
| Foreign Exchange rate Adjustments | -- | -110.16% | 99.41% | 3.82% | -115.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -126.95% | 111.40% | 216.01% | 26.15% |